デフォルト表紙
市場調査レポート
商品コード
1468402

In-vivo CRO市場レポート:タイプ別、GLPタイプ別、適応症別、地域別、2024~2032年

In-vivo CRO Market Report by Type (Rodent, Non-Rodent), GLP Type (Non-GLP, GLP Toxicology), Indication (Autoimmune/Inflammation Conditions, Pain Management, Oncology, CNS Conditions, Diabetes, Obesity, and Others), and Region 2024-2032

出版日: | 発行: IMARC | ページ情報: 英文 135 Pages | 納期: 2~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=160.10円
In-vivo CRO市場レポート:タイプ別、GLPタイプ別、適応症別、地域別、2024~2032年
出版日: 2024年04月08日
発行: IMARC
ページ情報: 英文 135 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のIn-vivo CRO市場規模は2023年に49億米ドルに達しました。今後、IMARC Groupは、2024~2032年にかけて7.12%の成長率(CAGR)を示し、2032年までに93億米ドルに達すると予測しています。

生体内医薬品開発業務受託機関(CRO)は、契約ベースで広範なバイオ医薬品研究を実施する機関です。アウトソーシングサービスを提供することで、製薬会社やバイオテクノロジー企業が効果的な医薬品、ワクチン、医療機器を処方できるよう支援しています。In-vitro CROと比較して、In-vivo CROは生体内で行われる研究を扱い、摘出した細胞や組織で試験を組織する代わりに、医薬品の安全性と有効性を評価するヒト臨床試験を実施します。複雑な医療的試験を管理し、最小限のコストで効果的な医薬品を開発し、雇用、資金調達、臨床準備に起因する遅延を回避してワークフローを最適化することで、研究機関を支援します。その結果、In-vivo CROは、疼痛管理、腫瘍学、中枢神経系(CNS)損傷やその他の疾患の治療に幅広く応用されています。現在、齧歯類ベースと非齧歯類ベースに二分されています。

In-vivo CRO市場の動向:

様々な心血管疾患、特に高齢者人口における有病率の増加、診断と治療のための効果的な薬剤や新規腫瘍学ベースの治療に対するニーズの高まりが、主に市場成長の原動力となっています。さらに、研究開発・製造受託機関(CRDMO)による医薬品有効成分(API)の臨床規模での製造需要の高まりや、モノクローナル抗体よりもバイオシミラーへの傾斜が、その他の成長促進要因として作用しています。さらに、健康への懸念が高まっていることから、バイオテクノロジー企業はCROと連携して効果的な新規ワクチンを開発するようになり、特にCOVID-19の大流行が市場成長に寄与しています。さらに、前臨床試験中に毒物学的と薬剤動態学的研究を実施するためにIn-vivo CROを幅広く利用することが、市場の成長を促しています。これとは別に、生物学的同等性の出現、ジェネリック医薬品の急成長、特許切れの進行、個別化医薬品を開発するための継続的な研究開発(R&D)活動が、市場に明るい展望をもたらしています。

本レポートで扱う主要質問

  • 2023年の世界のIn-vivo CRO市場規模は?
  • 2024~2032年の世界のIn-vivo CRO市場の予想成長率は?
  • 世界のIn-vivo CRO市場を牽引する主要因は何か?
  • COVID-19が世界のIn-vivo CRO市場に与えた影響は?
  • 世界のIn-vivo CRO市場のタイプ別区分は?
  • GLPタイプ別の世界のIn-vivo CRO市場の内訳は?
  • 適応症別のIn-vivo CRO世界市場の内訳は?
  • In-vivo CROの世界市場における主要地域は?
  • In-vivo CROの世界市場における主要参入企業は?

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 世界のIn-vivo CRO市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳:タイプ別

  • げっ歯類
    • 市場動向
    • 主要セグメント
      • ネズミ
      • マウス
      • その他
    • 市場予測
  • 非げっ歯類

第7章 市場内訳:GLPタイプ別

  • 非GLP
    • 市場動向
    • 主要セグメント
      • 社内
      • アウトソーシング
    • 市場予測
  • GLPトキシコロジー
    • 市場動向
    • 主要セグメント
      • 社内
      • アウトソーシング
    • 市場予測

第8章 市場内訳:適応症別

  • 自己免疫疾患/炎症疾患
    • 市場動向
    • 主要セグメント
      • 関節リウマチ
      • 多発性硬化症
      • 変形性関節症
      • 過敏性腸症候群
      • その他
    • 市場予測
  • 疼痛管理
    • 市場動向
    • 主要セグメント
      • 慢性疼痛
      • 急性痛
    • 市場予測
  • 腫瘍学
    • 市場動向
    • 主要セグメント
      • 血液がん
      • 固形がん
      • その他
    • 市場予測
  • 中枢神経系疾患
    • 市場動向
    • 主要セグメント
      • てんかん
      • パーキンソン病
      • ハンチントン病
      • 脳卒中
      • 外傷性脳損傷
      • 筋萎縮性側索硬化症
      • 筋再生
      • その他
    • 市場予測
  • 糖尿病
  • 肥満症
  • その他

第9章 市場内訳:地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳:国別
    • 市場予測

第10章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Charles River Laboratories International Inc.
    • Evotec SE
    • ICON plc
    • Iris Pharma(ABIONYX Pharma)
    • Labcorp Drug Development(Laboratory Corporation of America Holdings)
    • North American Science Associates LLC
    • Parexel International Corporation
    • Pharmaceutical Product Development Inc.(Thermo Fisher Scientific Inc.)
    • Pronexus Analytical AB
    • Syneos Health
    • WuXi AppTec
図表

List of Figures

  • Figure 1: Global: In-vivo CRO Market: Major Drivers and Challenges
  • Figure 2: Global: In-vivo CRO Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: In-vivo CRO Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: In-vivo CRO Market: Breakup by Type (in %), 2023
  • Figure 5: Global: In-vivo CRO Market: Breakup by GLP Type (in %), 2023
  • Figure 6: Global: In-vivo CRO Market: Breakup by Indication (in %), 2023
  • Figure 7: Global: In-vivo CRO Market: Breakup by Region (in %), 2023
  • Figure 8: Global: In-vivo CRO (Rodent) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: In-vivo CRO (Rodent) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: In-vivo CRO (Non-Rodent) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: In-vivo CRO (Non-Rodent) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: In-vivo CRO (Non-GLP) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: In-vivo CRO (Non-GLP) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: In-vivo CRO (GLP Toxicology) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: In-vivo CRO (GLP Toxicology) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: In-vivo CRO (Autoimmune/Inflammation Conditions) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: In-vivo CRO (Autoimmune/Inflammation Conditions) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: In-vivo CRO (Pain Management) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: In-vivo CRO (Pain Management) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: In-vivo CRO (Oncology) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: In-vivo CRO (Oncology) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: In-vivo CRO (CNS Conditions) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: In-vivo CRO (CNS Conditions) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: In-vivo CRO (Diabetes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: In-vivo CRO (Diabetes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: In-vivo CRO (Obesity) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: In-vivo CRO (Obesity) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: In-vivo CRO (Other Indications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: In-vivo CRO (Other Indications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: North America: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: North America: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: United States: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: United States: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Canada: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Canada: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Asia-Pacific: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Asia-Pacific: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: China: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: China: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: Japan: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: Japan: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: India: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: India: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: South Korea: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: South Korea: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Australia: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Australia: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Indonesia: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Indonesia: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Others: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Others: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Europe: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Europe: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Germany: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Germany: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: France: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: France: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: United Kingdom: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: United Kingdom: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Italy: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Italy: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Spain: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Spain: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Russia: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Russia: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Others: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Others: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Latin America: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Latin America: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Brazil: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Brazil: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Mexico: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Mexico: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Others: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Others: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Middle East and Africa: In-vivo CRO Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: Middle East and Africa: In-vivo CRO Market: Breakup by Country (in %), 2023
  • Figure 78: Middle East and Africa: In-vivo CRO Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: Global: In-vivo CRO Industry: SWOT Analysis
  • Figure 80: Global: In-vivo CRO Industry: Value Chain Analysis
  • Figure 81: Global: In-vivo CRO Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: In-vivo CRO Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: In-vivo CRO Market Forecast: Breakup by Type (in Million US$), 2024-2032
  • Table 3: Global: In-vivo CRO Market Forecast: Breakup by GLP Type (in Million US$), 2024-2032
  • Table 4: Global: In-vivo CRO Market Forecast: Breakup by Indication (in Million US$), 2024-2032
  • Table 5: Global: In-vivo CRO Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: In-vivo CRO Market: Competitive Structure
  • Table 7: Global: In-vivo CRO Market: Key Players
目次
Product Code: SR112024A6267

The global in-vivo CRO market size reached US$ 4.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 9.3 Billion by 2032, exhibiting a growth rate (CAGR) of 7.12% during 2024-2032.

In-vivo contract research organizations (CROs) are institutions that conduct extensive biopharmaceutical research on a contractual basis. They support pharmaceutical and biotechnology companies in formulating effective drugs, vaccines, and medical devices by providing outsourcing services. As compared to in-vitro CRO, in-vivo CRO deals with the research performed within the living organism and conducts human clinical trials to assess the safety and efficacy of the drugs instead of organizing examinations on removed cells and tissues. They aid research institutions in managing complex medical testing, developing effective medications at minimal costs, and optimizing workflow by avoiding delays caused by hiring, fundraising, and clinical preparations. As a result, in-vivo CRO finds extensive application in pain management, oncology, and treating central nervous system (CNS) injuries and other disorders. Currently, they are bifurcated into rodent- and non-rodent-based types.

In-vivo CRO Market Trends:

The increasing prevalence of various cardiovascular ailments, especially amongst the geriatric population, and the growing need for effective medications and novel oncology-based therapies for diagnosis and treatment are primarily driving the market growth. Additionally, the rising demand for clinical-scale manufacturing of active pharmaceutical ingredients (APIs) by contract research, development, and manufacturing organizations (CRDMOs) and the shifting inclination toward biosimilars over format monoclonal antibodies are acting as other growth-inducing factors. Furthermore, the fueling health concerns have prompted biotechnology companies to engineer effective novel vaccines in collaboration with CRO, especially during the COVID-19 pandemic, which is contributing to the market growth. Moreover, the extensive utilization of in-vivo CRO to perform toxicology and pharmacokinetic studies during preclinical activities is impelling the market growth. Apart from this, the advent of bioequivalence, rapid growth in generics, ongoing patent expirations, and continuous research and development (R&D) activities to engineer personalized medicines are creating a positive outlook for the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global in-vivo CRO market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type, GLP type and indication.

Breakup by Type:

Rodent

Rats

Mice

Others

Non-Rodent

Breakup by GLP Type:

Non-GLP

In House

Outsourcing

GLP Toxicology

In House

Outsourcing

Breakup by Indication:

Autoimmune/Inflammation Conditions

Rheumatoid Arthritis

Multiple Sclerosis

Osteoarthritis

Irritable Bowel Syndrome

Others

Pain Management

Chronic Pain

Acute Pain

Oncology

Blood Cancer

Solid Tumor

Others

CNS Conditions

Epilepsy

Parkinson's Disease

Huntington's Disease

Stroke

Traumatic Brain Injury

ALS

Muscle Regeneration

Others

Diabetes

Obesity

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Charles River Laboratories International Inc., Evotec SE, ICON plc, Iris Pharma (Abionyx Pharma), Labcorp Drug Development (Laboratory Corporation of America Holdings), North American Science Associates LLC, Parexel International Corporation, Pharmaceutical Product Development Inc. (Thermo Fisher Scientific Inc.), Pronexus Analytical AB, Syneos Health and WuXi AppTec.

Key Questions Answered in This Report

  • 1. What was the size of the global in-vivo CRO market in 2023?
  • 2. What is the expected growth rate of the global in-vivo CRO market during 2024-2032?
  • 3. What are the key factors driving the global in-vivo CRO market?
  • 4. What has been the impact of COVID-19 on the global in-vivo CRO market?
  • 5. What is the breakup of the global in-vivo CRO market based on the type?
  • 6. What is the breakup of the global in-vivo CRO market based on the GLP type?
  • 7. What is the breakup of the global in-vivo CRO market based on indication?
  • 8. What are the key regions in the global in-vivo CRO market?
  • 9. Who are the key players/companies in the global in-vivo CRO market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global In-vivo CRO Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Rodent
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Rats
      • 6.1.2.2 Mice
      • 6.1.2.3 Others
    • 6.1.3 Market Forecast
  • 6.2 Non-Rodent
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by GLP Type

  • 7.1 Non-GLP
    • 7.1.1 Market Trends
    • 7.1.2 Key Segments
      • 7.1.2.1 In House
      • 7.1.2.2 Outsourcing
    • 7.1.3 Market Forecast
  • 7.2 GLP Toxicology
    • 7.2.1 Market Trends
    • 7.2.2 Key Segments
      • 7.2.2.1 In House
      • 7.2.2.2 Outsourcing
    • 7.2.3 Market Forecast

8 Market Breakup by Indication

  • 8.1 Autoimmune/Inflammation Conditions
    • 8.1.1 Market Trends
    • 8.1.2 Key Segments
      • 8.1.2.1 Rheumatoid Arthritis
      • 8.1.2.2 Multiple Sclerosis
      • 8.1.2.3 Osteoarthritis
      • 8.1.2.4 Irritable Bowel Syndrome
      • 8.1.2.5 Others
    • 8.1.3 Market Forecast
  • 8.2 Pain Management
    • 8.2.1 Market Trends
    • 8.2.2 Key Segments
      • 8.2.2.1 Chronic Pain
      • 8.2.2.2 Acute Pain
    • 8.2.3 Market Forecast
  • 8.3 Oncology
    • 8.3.1 Market Trends
    • 8.3.2 Key Segments
      • 8.3.2.1 Blood Cancer
      • 8.3.2.2 Solid Tumor
      • 8.3.2.3 Others
    • 8.3.3 Market Forecast
  • 8.4 CNS Conditions
    • 8.4.1 Market Trends
    • 8.4.2 Key Segments
      • 8.4.2.1 Epilepsy
      • 8.4.2.2 Parkinson's Disease
      • 8.4.2.3 Huntington's Disease
      • 8.4.2.4 Stroke
      • 8.4.2.5 Traumatic Brain Injury
      • 8.4.2.6 ALS
      • 8.4.2.7 Muscle Regeneration
      • 8.4.2.8 Others
    • 8.4.3 Market Forecast
  • 8.5 Diabetes
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Obesity
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast
  • 8.7 Others
    • 8.7.1 Market Trends
    • 8.7.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Charles River Laboratories International Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Evotec SE
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 ICON plc
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Iris Pharma (ABIONYX Pharma)
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Labcorp Drug Development (Laboratory Corporation of America Holdings)
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 SWOT Analysis
    • 14.3.6 North American Science Associates LLC
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
    • 14.3.7 Parexel International Corporation
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 SWOT Analysis
    • 14.3.8 Pharmaceutical Product Development Inc. (Thermo Fisher Scientific Inc.)
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
    • 14.3.9 Pronexus Analytical AB
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
    • 14.3.10 Syneos Health
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 WuXi AppTec
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials